The Impact of Drug Shortages on Patients with Cardiovascular Disease: Causes, Consequences, and a Call to Action
Abstract Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in th...
Gespeichert in:
Veröffentlicht in: | The American heart journal 2016-05, Vol.175, p.130-141 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 141 |
---|---|
container_issue | |
container_start_page | 130 |
container_title | The American heart journal |
container_volume | 175 |
creator | Reed, Brent N., PharmD, FAHA Fox, Erin R., PharmD Konig, Madeleine, MPH Jackevicius, Cynthia A., PharmD, MSc, FAHA Masoudi, Frederick A., MD, MSPH, FAHA Rabinstein, Alejandro A., MD, FAHA Page, Robert L., PharmD, MSPH, FAHA |
description | Abstract Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in the regulatory environment have led to some improvements in recent years, problems involving manufacturing processes remain the most common underlying cause. Due to the complex nature of drug shortages, sustainable solutions to prevent and mitigate them will require collaboration between regulatory agencies, drug manufacturers, and other key stakeholder groups. In this report, we describe the scope of the cardiovascular drug shortage crisis in the United States, including its underlying causes and the efforts currently being made to address it. Further, we provide specific recommendations for how cardiovascular care professionals can be involved in efforts to limit the impact of drug shortages on patient care as well as policy changes aimed at preventing and mitigating them. |
doi_str_mv | 10.1016/j.ahj.2016.02.004 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811898707</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S000287031600048X</els_id><sourcerecordid>4062808261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-14e8258a2e41e8f7599e9bae301dbc6acfd6c1b4aa4d3c1678f3f05fe383bd7c3</originalsourceid><addsrcrecordid>eNqFkl1rFTEQhoMo9lj9Ad5IwBsv3DVfZ5NYEMqpH4WCQit4F7LZ2Z6sezbHJFvpvzfLqQq90KvMJM87ZOYdhJ5TUlNCmzdDbbdDzUpYE1YTIh6gFSVaVo0U4iFaEUJYpSThR-hJSkNJG6aax-iISSq15GyF9ldbwOe7vXUZhx6fxfkaX25DzPYaEg4T_mKzhykn_NPnLd7Y2PlwY5ObRxvxmU9gE7wt93OC9BpvwpTgxwyTWzI7ddiWt3HEOeBTl32YnqJHvR0TPLs7j9HXD--vNp-qi88fzzenF5UTjc4VFaDYWlkGgoLq5Vpr0K0FTmjXusa6vmscbYW1ouOONlL1vCfrHrjibScdP0avDnX3MZQPpWx2PjkYRztBmJOhilKly3Dk_1GptNCKcVbQl_fQIcxxKo0UShMq1orRQtED5WJIKUJv9tHvbLw1lJjFOTOY4pxZnDOEmeJc0by4qzy3O-j-KH5bVYCTAwBlajceoknOL4PufASXTRf8P8u_u6d2o5-8s-N3uIX0twuTisBcLquzbA5tSiTUN_4LFVi8uQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1790145821</pqid></control><display><type>article</type><title>The Impact of Drug Shortages on Patients with Cardiovascular Disease: Causes, Consequences, and a Call to Action</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Reed, Brent N., PharmD, FAHA ; Fox, Erin R., PharmD ; Konig, Madeleine, MPH ; Jackevicius, Cynthia A., PharmD, MSc, FAHA ; Masoudi, Frederick A., MD, MSPH, FAHA ; Rabinstein, Alejandro A., MD, FAHA ; Page, Robert L., PharmD, MSPH, FAHA</creator><creatorcontrib>Reed, Brent N., PharmD, FAHA ; Fox, Erin R., PharmD ; Konig, Madeleine, MPH ; Jackevicius, Cynthia A., PharmD, MSc, FAHA ; Masoudi, Frederick A., MD, MSPH, FAHA ; Rabinstein, Alejandro A., MD, FAHA ; Page, Robert L., PharmD, MSPH, FAHA</creatorcontrib><description>Abstract Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in the regulatory environment have led to some improvements in recent years, problems involving manufacturing processes remain the most common underlying cause. Due to the complex nature of drug shortages, sustainable solutions to prevent and mitigate them will require collaboration between regulatory agencies, drug manufacturers, and other key stakeholder groups. In this report, we describe the scope of the cardiovascular drug shortage crisis in the United States, including its underlying causes and the efforts currently being made to address it. Further, we provide specific recommendations for how cardiovascular care professionals can be involved in efforts to limit the impact of drug shortages on patient care as well as policy changes aimed at preventing and mitigating them.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2016.02.004</identifier><identifier>PMID: 27179732</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiovascular ; Cardiovascular Agents - supply & distribution ; Cardiovascular disease ; Cardiovascular Diseases - drug therapy ; Diuretics ; Dopamine ; Drug stores ; Electrolytes ; Health Services Accessibility - standards ; Health Services Needs and Demand ; Humans ; Manufacturers ; Manufacturing ; Patients ; Pharmaceutical industry ; Prescription drugs ; Public health ; Quality Improvement ; Shortages ; Thrombosis ; United States</subject><ispartof>The American heart journal, 2016-05, Vol.175, p.130-141</ispartof><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited May 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-14e8258a2e41e8f7599e9bae301dbc6acfd6c1b4aa4d3c1678f3f05fe383bd7c3</citedby><cites>FETCH-LOGICAL-c469t-14e8258a2e41e8f7599e9bae301dbc6acfd6c1b4aa4d3c1678f3f05fe383bd7c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1790145821?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27928,27929,45999,64389,64391,64393,72473</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27179732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reed, Brent N., PharmD, FAHA</creatorcontrib><creatorcontrib>Fox, Erin R., PharmD</creatorcontrib><creatorcontrib>Konig, Madeleine, MPH</creatorcontrib><creatorcontrib>Jackevicius, Cynthia A., PharmD, MSc, FAHA</creatorcontrib><creatorcontrib>Masoudi, Frederick A., MD, MSPH, FAHA</creatorcontrib><creatorcontrib>Rabinstein, Alejandro A., MD, FAHA</creatorcontrib><creatorcontrib>Page, Robert L., PharmD, MSPH, FAHA</creatorcontrib><title>The Impact of Drug Shortages on Patients with Cardiovascular Disease: Causes, Consequences, and a Call to Action</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Abstract Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in the regulatory environment have led to some improvements in recent years, problems involving manufacturing processes remain the most common underlying cause. Due to the complex nature of drug shortages, sustainable solutions to prevent and mitigate them will require collaboration between regulatory agencies, drug manufacturers, and other key stakeholder groups. In this report, we describe the scope of the cardiovascular drug shortage crisis in the United States, including its underlying causes and the efforts currently being made to address it. Further, we provide specific recommendations for how cardiovascular care professionals can be involved in efforts to limit the impact of drug shortages on patient care as well as policy changes aimed at preventing and mitigating them.</description><subject>Cardiovascular</subject><subject>Cardiovascular Agents - supply & distribution</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Diuretics</subject><subject>Dopamine</subject><subject>Drug stores</subject><subject>Electrolytes</subject><subject>Health Services Accessibility - standards</subject><subject>Health Services Needs and Demand</subject><subject>Humans</subject><subject>Manufacturers</subject><subject>Manufacturing</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Prescription drugs</subject><subject>Public health</subject><subject>Quality Improvement</subject><subject>Shortages</subject><subject>Thrombosis</subject><subject>United States</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkl1rFTEQhoMo9lj9Ad5IwBsv3DVfZ5NYEMqpH4WCQit4F7LZ2Z6sezbHJFvpvzfLqQq90KvMJM87ZOYdhJ5TUlNCmzdDbbdDzUpYE1YTIh6gFSVaVo0U4iFaEUJYpSThR-hJSkNJG6aax-iISSq15GyF9ldbwOe7vXUZhx6fxfkaX25DzPYaEg4T_mKzhykn_NPnLd7Y2PlwY5ObRxvxmU9gE7wt93OC9BpvwpTgxwyTWzI7ddiWt3HEOeBTl32YnqJHvR0TPLs7j9HXD--vNp-qi88fzzenF5UTjc4VFaDYWlkGgoLq5Vpr0K0FTmjXusa6vmscbYW1ouOONlL1vCfrHrjibScdP0avDnX3MZQPpWx2PjkYRztBmJOhilKly3Dk_1GptNCKcVbQl_fQIcxxKo0UShMq1orRQtED5WJIKUJv9tHvbLw1lJjFOTOY4pxZnDOEmeJc0by4qzy3O-j-KH5bVYCTAwBlajceoknOL4PufASXTRf8P8u_u6d2o5-8s-N3uIX0twuTisBcLquzbA5tSiTUN_4LFVi8uQ</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Reed, Brent N., PharmD, FAHA</creator><creator>Fox, Erin R., PharmD</creator><creator>Konig, Madeleine, MPH</creator><creator>Jackevicius, Cynthia A., PharmD, MSc, FAHA</creator><creator>Masoudi, Frederick A., MD, MSPH, FAHA</creator><creator>Rabinstein, Alejandro A., MD, FAHA</creator><creator>Page, Robert L., PharmD, MSPH, FAHA</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20160501</creationdate><title>The Impact of Drug Shortages on Patients with Cardiovascular Disease: Causes, Consequences, and a Call to Action</title><author>Reed, Brent N., PharmD, FAHA ; Fox, Erin R., PharmD ; Konig, Madeleine, MPH ; Jackevicius, Cynthia A., PharmD, MSc, FAHA ; Masoudi, Frederick A., MD, MSPH, FAHA ; Rabinstein, Alejandro A., MD, FAHA ; Page, Robert L., PharmD, MSPH, FAHA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-14e8258a2e41e8f7599e9bae301dbc6acfd6c1b4aa4d3c1678f3f05fe383bd7c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cardiovascular</topic><topic>Cardiovascular Agents - supply & distribution</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Diuretics</topic><topic>Dopamine</topic><topic>Drug stores</topic><topic>Electrolytes</topic><topic>Health Services Accessibility - standards</topic><topic>Health Services Needs and Demand</topic><topic>Humans</topic><topic>Manufacturers</topic><topic>Manufacturing</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Prescription drugs</topic><topic>Public health</topic><topic>Quality Improvement</topic><topic>Shortages</topic><topic>Thrombosis</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reed, Brent N., PharmD, FAHA</creatorcontrib><creatorcontrib>Fox, Erin R., PharmD</creatorcontrib><creatorcontrib>Konig, Madeleine, MPH</creatorcontrib><creatorcontrib>Jackevicius, Cynthia A., PharmD, MSc, FAHA</creatorcontrib><creatorcontrib>Masoudi, Frederick A., MD, MSPH, FAHA</creatorcontrib><creatorcontrib>Rabinstein, Alejandro A., MD, FAHA</creatorcontrib><creatorcontrib>Page, Robert L., PharmD, MSPH, FAHA</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reed, Brent N., PharmD, FAHA</au><au>Fox, Erin R., PharmD</au><au>Konig, Madeleine, MPH</au><au>Jackevicius, Cynthia A., PharmD, MSc, FAHA</au><au>Masoudi, Frederick A., MD, MSPH, FAHA</au><au>Rabinstein, Alejandro A., MD, FAHA</au><au>Page, Robert L., PharmD, MSPH, FAHA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Drug Shortages on Patients with Cardiovascular Disease: Causes, Consequences, and a Call to Action</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>175</volume><spage>130</spage><epage>141</epage><pages>130-141</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Abstract Shortages of cardiovascular drugs have become increasingly common, representing an ongoing public health crisis. Given few therapeutic alternatives to many of the drugs in short supply, these shortages also pose a major challenge for cardiovascular care professionals. Although changes in the regulatory environment have led to some improvements in recent years, problems involving manufacturing processes remain the most common underlying cause. Due to the complex nature of drug shortages, sustainable solutions to prevent and mitigate them will require collaboration between regulatory agencies, drug manufacturers, and other key stakeholder groups. In this report, we describe the scope of the cardiovascular drug shortage crisis in the United States, including its underlying causes and the efforts currently being made to address it. Further, we provide specific recommendations for how cardiovascular care professionals can be involved in efforts to limit the impact of drug shortages on patient care as well as policy changes aimed at preventing and mitigating them.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27179732</pmid><doi>10.1016/j.ahj.2016.02.004</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-8703 |
ispartof | The American heart journal, 2016-05, Vol.175, p.130-141 |
issn | 0002-8703 1097-6744 |
language | eng |
recordid | cdi_proquest_miscellaneous_1811898707 |
source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
subjects | Cardiovascular Cardiovascular Agents - supply & distribution Cardiovascular disease Cardiovascular Diseases - drug therapy Diuretics Dopamine Drug stores Electrolytes Health Services Accessibility - standards Health Services Needs and Demand Humans Manufacturers Manufacturing Patients Pharmaceutical industry Prescription drugs Public health Quality Improvement Shortages Thrombosis United States |
title | The Impact of Drug Shortages on Patients with Cardiovascular Disease: Causes, Consequences, and a Call to Action |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T21%3A05%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Drug%20Shortages%20on%20Patients%20with%20Cardiovascular%20Disease:%20Causes,%20Consequences,%20and%20a%20Call%20to%20Action&rft.jtitle=The%20American%20heart%20journal&rft.au=Reed,%20Brent%20N.,%20PharmD,%20FAHA&rft.date=2016-05-01&rft.volume=175&rft.spage=130&rft.epage=141&rft.pages=130-141&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2016.02.004&rft_dat=%3Cproquest_cross%3E4062808261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1790145821&rft_id=info:pmid/27179732&rft_els_id=1_s2_0_S000287031600048X&rfr_iscdi=true |